Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 5/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | CFD | P00746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91471 | 0.86 | MAPK14 (0.39) | MAPK14L3MBTL1MAPTKMT2A | |
| SCHEMBL84421 | 0.83 | SMN1; SMN2 (0.37) | MAPK14BRAFACACBMAPK1KMT2A | |
| SCHEMBL84410 | 0.81 | ACACB (0.40) | BRAFACACB | |
| SCHEMBL14004969 | 0.74 | MAPK14 (0.44) | MAPK14ACACBIDH1MAPK8KMT2A | |
| SCHEMBL84017 | 0.72 | ALDH1A1 (0.42) | MAPK14L3MBTL1KMT2A | |
| SCHEMBL84098 | 0.71 | BRAF (0.46) | BRAF | |
| SCHEMBL91474 | 0.69 | MAPK14 (0.41) | MAPK14L3MBTL1KMT2A | |
| SCHEMBL84413 | 0.69 | HRH4 (0.49) | ACACBIDH1MAPK8KMT2A | |
| SCHEMBL84383 | 0.68 | SYK (0.40) | BRAFACACB | |
| SCHEMBL84101 | 0.68 | ACACB (0.50) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MAPK14 484/4885BRAF 1/4885ACACB 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.